endpts.com·May 11, 2026
Inhibrx, a biotech company based in San Diego, reports that its experimental drug INBRX-106, when combined with Merck's Keytruda, was more effective in shrinking tumors in patients with metastatic head cancer than Keytruda alone.
Inhibrx's experimental drug INBRX-106, when combined with Merck's Keytruda, demonstrated superior tumor shrinkage in patients with metastatic head cancer compared to Keytruda alone. This presents a significant advancement in combination therapies and could signal a promising avenue for investment and clinical trials in oncology-focused biotech companies.